Since its inception, in 1916, the Department of Pathology has built a strong program in basic, clinical, and translational research. We currently hold over 50 active research grants. Please explore the links to our Principal Investigators pages (below) for more information on the research currently underway.
cancer cachexia, muscle physiology, muscle pathology, cancer-associated musculoskeletal disease, sarcopenia of aging, IL-6, STAT3, RANKL, chemotherapy toxicities, ovarian cancer, colorectal cancer, tumor-host interactions, muscular dystrophy
UNDERGRADUATE
University of Torino, Italy
MSc., Industrial Biotechnology
07/2004
GRADUATE
University of Torino, Italy
Ph.D., Experimental Pathology
11/2008
POSTDOCTORAL
University of Genova, Italy
Post-Doc, Neuromuscular diseases
01/2009 – 01/2010
University of Miami Miller School of Medicine, Miami, FL
Post-Doc, Cancer cachexia
03/2010 – 07/2011
Thomas Jefferson University, Philadelphia, PA
Post-Doc, Cancer cachexia
08/2011 – 07/2013
R21 CA190028-01 (NIH/NCI)
(PQB-3) Roles of skeletal muscle mass in chemotherapy-associated cachexia
09/2014 - 08/2016
V2017-021 (V Foundation Scholar Grant)
Mechanisms and treatment of chemotherapy-induced cachexia and muscle weakness
11/2017 - 10/2019
Research Scholar
Showalter Research Trust
07/2018
Excellence in Research
4th Cancer Cachexia Conference
09/2018
132013-RSG-18-010-01-CCG (American Cancer Society)
Mechanisms of chemotherapy-induced muscle weakness and fatigue
07/2018 - 06/2022
R01 AR079379 (NIH/NIAMS)
Targeting RANKL for the treatment of muscle and bone defects in cachexia
07/2021 - 06/2026
R01 AR080051 (NIH/NIAMS)
IGFBP1 mediates a liver-bone-muscle axis in colorectal cancer cachexia
08/2022 – 07/2027
-Department of Pathology, University of Colorado Anschutz Medical Campus
-University of Colorado Comprehensive Cancer Center
cancer cachexia, muscle physiology, muscle pathology, cancer-associated musculoskeletal disease, sarcopenia of aging, IL-6, STAT3, RANKL, chemotherapy toxicities, ovarian cancer, colorectal cancer, tumor-host interactions, muscular dystrophy
UNDERGRADUATE
University of Torino, Italy
MSc., Industrial Biotechnology
07/2004
GRADUATE
University of Torino, Italy
Ph.D., Experimental Pathology
11/2008
POSTDOCTORAL
University of Genova, Italy
Post-Doc, Neuromuscular diseases
01/2009 – 01/2010
University of Miami Miller School of Medicine, Miami, FL
Post-Doc, Cancer cachexia
03/2010 – 07/2011
Thomas Jefferson University, Philadelphia, PA
Post-Doc, Cancer cachexia
08/2011 – 07/2013
R21 CA190028-01 (NIH/NCI)
(PQB-3) Roles of skeletal muscle mass in chemotherapy-associated cachexia
09/2014 - 08/2016
V2017-021 (V Foundation Scholar Grant)
Mechanisms and treatment of chemotherapy-induced cachexia and muscle weakness
11/2017 - 10/2019
Research Scholar
Showalter Research Trust
07/2018
Excellence in Research
4th Cancer Cachexia Conference
09/2018
132013-RSG-18-010-01-CCG (American Cancer Society)
Mechanisms of chemotherapy-induced muscle weakness and fatigue
07/2018 - 06/2022
R01 AR079379 (NIH/NIAMS)
Targeting RANKL for the treatment of muscle and bone defects in cachexia
07/2021 - 06/2026
R01 AR080051 (NIH/NIAMS)
IGFBP1 mediates a liver-bone-muscle axis in colorectal cancer cachexia
08/2022 – 07/2027
-Department of Pathology, University of Colorado Anschutz Medical Campus
-University of Colorado Comprehensive Cancer Center
cancer cachexia, muscle physiology, muscle pathology, cancer-associated musculoskeletal disease, sarcopenia of aging, IL-6, STAT3, RANKL, chemotherapy toxicities, ovarian cancer, colorectal cancer, tumor-host interactions, muscular dystrophy
UNDERGRADUATE
University of Torino, Italy
MSc., Industrial Biotechnology
07/2004
GRADUATE
University of Torino, Italy
Ph.D., Experimental Pathology
11/2008
POSTDOCTORAL
University of Genova, Italy
Post-Doc, Neuromuscular diseases
01/2009 – 01/2010
University of Miami Miller School of Medicine, Miami, FL
Post-Doc, Cancer cachexia
03/2010 – 07/2011
Thomas Jefferson University, Philadelphia, PA
Post-Doc, Cancer cachexia
08/2011 – 07/2013
R21 CA190028-01 (NIH/NCI)
(PQB-3) Roles of skeletal muscle mass in chemotherapy-associated cachexia
09/2014 - 08/2016
V2017-021 (V Foundation Scholar Grant)
Mechanisms and treatment of chemotherapy-induced cachexia and muscle weakness
11/2017 - 10/2019
Research Scholar
Showalter Research Trust
07/2018
Excellence in Research
4th Cancer Cachexia Conference
09/2018
132013-RSG-18-010-01-CCG (American Cancer Society)
Mechanisms of chemotherapy-induced muscle weakness and fatigue
07/2018 - 06/2022
R01 AR079379 (NIH/NIAMS)
Targeting RANKL for the treatment of muscle and bone defects in cachexia
07/2021 - 06/2026
R01 AR080051 (NIH/NIAMS)
IGFBP1 mediates a liver-bone-muscle axis in colorectal cancer cachexia
08/2022 – 07/2027
-Department of Pathology, University of Colorado Anschutz Medical Campus
-University of Colorado Comprehensive Cancer Center
cancer cachexia, muscle physiology, muscle pathology, cancer-associated musculoskeletal disease, sarcopenia of aging, IL-6, STAT3, RANKL, chemotherapy toxicities, ovarian cancer, colorectal cancer, tumor-host interactions, muscular dystrophy
UNDERGRADUATE
University of Torino, Italy
MSc., Industrial Biotechnology
07/2004
GRADUATE
University of Torino, Italy
Ph.D., Experimental Pathology
11/2008
POSTDOCTORAL
University of Genova, Italy
Post-Doc, Neuromuscular diseases
01/2009 – 01/2010
University of Miami Miller School of Medicine, Miami, FL
Post-Doc, Cancer cachexia
03/2010 – 07/2011
Thomas Jefferson University, Philadelphia, PA
Post-Doc, Cancer cachexia
08/2011 – 07/2013
R21 CA190028-01 (NIH/NCI)
(PQB-3) Roles of skeletal muscle mass in chemotherapy-associated cachexia
09/2014 - 08/2016
V2017-021 (V Foundation Scholar Grant)
Mechanisms and treatment of chemotherapy-induced cachexia and muscle weakness
11/2017 - 10/2019
Research Scholar
Showalter Research Trust
07/2018
Excellence in Research
4th Cancer Cachexia Conference
09/2018
132013-RSG-18-010-01-CCG (American Cancer Society)
Mechanisms of chemotherapy-induced muscle weakness and fatigue
07/2018 - 06/2022
R01 AR079379 (NIH/NIAMS)
Targeting RANKL for the treatment of muscle and bone defects in cachexia
07/2021 - 06/2026
R01 AR080051 (NIH/NIAMS)
IGFBP1 mediates a liver-bone-muscle axis in colorectal cancer cachexia
08/2022 – 07/2027
-Department of Pathology, University of Colorado Anschutz Medical Campus
-University of Colorado Comprehensive Cancer Center